Storia in 3 fonti

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

Cipla shares dip after Qilu deal as Morgan Stanley warns of a competitive biosimilars market impacting pricing and growth.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

Cipla shares dip after Qilu deal as Morgan Stanley warns of a competitive biosimilars market impacting pricing and growth.

Cipla partners with Qilu Pharma to develop and commercialize a cancer biosimilar, enhancing its oncology portfolio in the U.S.